![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ELAN SUES ABRAXIS BIOSCIENCE FOR PATENT INFRINGEMENT
ELAN SUES ABRAXIS BIOSCIENCE FOR PATENT INFRINGEMENT
July 20, 2006
Irish drug maker Elan Corp. has accused rival Abraxis Bioscience Inc. of infringing its patents by selling the breast cancer treatment Abraxane. A lawsuit filed Wednesday in a Delaware federal court says Abraxane, a nano-particle formulation of paclitaxel, trespasses on two patents issued in the 1990s that cover methods of formulating anti cancer drugs.
Market Watch
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct